Cardiac side effects of trastuzumab in breast cancer patients – single center experiences

Joanna Huszno, Dominika Leś, Danuta Sarzyczny-Słota, Elżbieta Nowara

Clinical and Experimental Oncology Department, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland

Introduction

Trastuzumab is a humanized monoclonal antibody, selectively targeted at the extracellular domain of human epidermal growth factor receptor 2 (HER-2). Overexpression of HER2 or amplification of the HER2 gene occurs in about 20% of breast cancer patients [1]. Due to the widespread use of trastuzumab in breast cancer therapy, special caution in the qualification for treatment is necessary and also careful monitoring during patients’ treatment to detect potential complications. One of the most common side effects of trastuzumab treatment is cardiotoxicity manifested as heart failure, accompanied by a decrease in left ventricular ejection fraction (LVEF) or an asymptomatic decrease in LVEF. The incidence of myocardial dysfunction during trastuzumab monotherapy is estimated at about 4–7%, including about 3% for toxicity grade 3 and 4 according to CTCAE (Common Terminology Criteria for Adverse Events) [2, 3]. Cardiotoxicity in treatment regimens containing anthracyclines can even reach 27% [3]. As opposed to the risk of cardiac side effects developing as a consequence of anthracycline treatment, the risk of trastuzumab-induced cardiomyopathy does not depend on the total dose of the drug [4]. The mechanism underlying trastuzumab-induced cardiomyopathy is not entirely clear. Some authors believe that it may be linked to the presence of the HER2 receptor on the surface of cardiomyocytes. Human epidermal growth factor receptor 2 is a receptor which plays an important role in cardiogenesis and myocardial protection against harmful factors such as ischaemia or adrenergic stimulation. Trastuzumab blocks the HER2 receptor by binding to its extracellular domain. Suppression of signal transduction inhibits repair mechanisms and promotes cardiomyocyte apoptosis [5]. Prior use of anthracyclines reduces the number of receptors on the surface of myocardial cells, which then are additionally blocked by trastuzumab [6]. Echocardiography is a routine method for monitoring cardiac side effects. Assessment includes measurement of parameters for systolic and diastolic function as well as anatomical cardiac dimensions. Simpson’s method is recommended for assessment of ejection fraction [7–9]. Abnormalities of right ventricular contractility, ventricular dilation and abnormalities of left ventricular contractility are the earliest manifestations of myocardial damage diagnosed by echocardiography. In case of clinical symptoms of heart failure, therapy must be stopped as well. Patients with an asymptomatic decrease in LVEF by 15% (or by 10%, if the acceptable lower LVEF limit is assumed as 50%) also require discontinuation of trastuzumab therapy [10]. Both scenarios require cardiac treatment. After normalization of LVEF or resolution of clinical symptoms, the decision to treat with trastuzumab is based on careful risk-benefit analysis for an individual patient. Major risk factors for cardiac side effects are: age over 65 years, prior anthracycline therapy, history of radiotherapy to the left side of the chest, obesity (BMI > 25 kg/m²), diabetes and hypertension. The study outlines the
authors’ own experience in a risk assessment of cardiac side effects in a group of trastuzumab-treated breast cancer patients.

**Material and methods**

The retrospective study was conducted on a group of 120 women treated in the Clinical and Experimental Oncology Department of the Oncology Centre – Maria Sklodowska-Curie Memorial Institute (Gliwice Branch), between the years 2006 and 2011. The study group comprised breast cancer patients with HER2 receptor overexpression or HER2 gene amplification. Human epidermal growth factor receptor 2 overexpression was assessed using an immunohistochemical method (IHM) in postoperative specimens or in samples obtained by thick needle biopsy. HER2 gene amplification was additionally assessed by FISH in 8 patients. Inclusion criteria were: baseline LVEF > 50% and medical history without major pathologies, such as unstable ischaemic heart disease, valvular heart disease, chronic hypertension with cardiovascular problems or uncontrolled diabetes (uncontrolled diabetes was classified as a random blood glucose level ≥ 11.0 mmol/l in diabetic patients). Patients’ characteristics are shown in Table 1.

Echocardiography was performed every 3 months during trastuzumab therapy and also before and after the anthracyclines. Cardiac side effects were assessed according to the NYHA (New York Heart Association) classification and on the CTCAE scale (ver. 4.0). Left ventricular ejection fraction decrease, abnormalities of right ventricular contractility, ventricular dilation and abnormalities of left ventricular contractility were the earliest manifestations of myocardial damage diagnosed by echocardiography.

The following factors were analyzed to determine their potential impact on the development of cardiac side effects: age at disease onset, menopausal status, smoking, hormone receptor status, previous chemotherapy containing anthracyclines, previous radiotherapy to the left side of the chest, comorbidities (diabetes, hypertension, obesity) and baseline LVEF.

Statistical analysis was performed using STATISTICA 7 (StatSoft). Univariate Cox analysis was conducted to assess the impact of risk factors on the development of cardiac side effects. Statistical inference was based on the p value determined using a one-sided test and 95% confidence intervals. Differences were considered as statistically significant if the p value was < 0.05. Confounding and effect-modifying variables were studied by multivariate analysis.

**Results**

The median age was 54 ±10.4 years (range: 24–71 years). Twenty percent of patients were older than 60 years. Surgery was performed on 100 (83%) patients (of whom 20 patients underwent BCT). In 20 (17%) patients operation was impossible due to advanced stage of disease. The studied group contained 74 (62%) early breast cancer patients and 46 (38%) metastatic patients. Adjuvant chemotherapy was given to 113 (94%) patients and adjuvant radiotherapy to 91 (76%) patients. FAC (5-fluorouracil 500 mg/m², adriamycin 50 mg/m², cyclophosphamide 500 mg/m²) was the most common chemotherapy regimen. The other used regimens were AC (adriamycin 60 mg/m², cyclophosphamide 600 mg/m²), AT (adriamycin 50 mg/m², docetaxel 75 mg/m²) and TAC (docetaxel 75 mg/m², adriamycin 50 mg/m², cyclophosphamide 500 mg/m²). Estrogen receptor expression was identified in 66 (55%) patients and progesterone receptor expression in 55 (45%) patients. Both steroid receptors were negative in 48 (40%) women. Trastuzumab was used for adjuvant therapy in 74 (62%) patients, and for the treatment of metastatic disease in 46 patients (38%), including 15 patients who underwent immunotherapy in second-line systemic treatment. Adjuvant trastuzumab was given after anthracyclines to 74 (62%) patients and simultaneously with taxanes to 46 (38%) patients. Adjuvant therapy consisted of 18 infusions of trastuzumab. Patients treated for metastatic disease received between 2 and 118 infusions (median number: 23).

During trastuzumab therapy, a total of 56 patients (47%) had reduced LVEF in comparison with baseline values. The LVEF reduction observed in the majority of patients (46 individuals, 39%) was clinically insignificant, not

| Table 1. Patient characteristics |
|---------------------------------|
|                                 |
| **Age, years**                  |
| < 65 years                      | 108 | 90 |
| > 65 years                      | 12  | 10 |
| **Menopausal status**           |
| pre-menopause                   | 31  | 26 |
| post-menopause                  | 89  | 74 |
| **Early breast cancer**         |
| yes                            | 74  | 62 |
| no                             | 46  | 38 |
| **History of smoking**          |
| yes                            | 37  | 31 |
| no                             | 83  | 69 |
| **Hormonal receptor status**    |
| positive                       | 48  | 40 |
| negative                       | 72  | 60 |
| **ER**                          |
| ER+                            | 66  | 55 |
| ER-                            | 54  | 45 |
| **PR**                          |
| PR+                            | 55  | 45 |
| PR-                            | 65  | 54 |
| **Radiotherapy**                |
| yes                            | 91  | 76 |
| no                             | 29  | 24 |
| **Priori left-sided radiotherapy** |
| yes                            | 49  | 54 |
| no                             | 48  | 40 |
| **Anthracycline exposure**      |
| yes                            | 109 | 91 |
| no                             | 11  | 9  |
| **Diabetes mellitus**           |
| yes                            | 4   | 3.4 |
| no                             | 11  | 9  |
| **Hypertension**                |
| yes                            | 10  | 8  |
| no                             | 22  | 18 |
aconsiderable limitation of physical activity, heart palpi-
tations and dyspnea developed in two patients, while abnor-
mal contractility (generalized hypokinesia) occurred in five
patients. Among patients requiring cardiac treatment only
one woman was older than 65 years. Four patients received
trastuzumab for metastatic disease (9% of all patients with
metastatic diseases) and six patients in adjuvant treatment
(8% of all patients receiving adjuvant treatment). 109 (91%)
women were previously treated with chemotherapy
containing anthracyclines and 49 (54%) of them received
radiotherapy to the left side of the chest. Furthermore, no
steroid receptor expression (either ER or PR) in tumor was
detected in any of those patients. Appropriate cardiac treat-
ment improved the cardiac status and normalized LVEF in
five patients and it allowed immunotherapy to be reintro-
duced. No cardiac status improvement was achieved in the
remaining five patients who required premature discon-
tinuation of immunotherapy. Univariate Cox analysis
demonstrated cardiac side effects in 4.2% of patients pre-
viously treated with radiotherapy applied to the left side of
the chest, and in 3.3% of patients who did not have radio-
therapy to that area of the body (p = 0.05). In the multivariate
analysis patients receiving radiotherapy were more likely to
develop cardiotoxicity if they were older (p = 0.0003). In the
analyzed group patients had baseline LVEF ranging between
50% and 70%. Left ventricular ejection fraction values
between 50% and 60% were noted in 77 patients (64%) and
between 60% and 70% in 43 women (36%). Cardiac side
effects occurred in nine patients with baseline LVEF
between 50% and 60%, and in one patient whose LVEF was
70% (p < 0.0001). No relationship was confirmed between
the number of trastuzumab infusions and LVEF decrease.
A decrease of LVEF was frequently observed in patients with
higher BMI (p = 0.05). A full description of LVEF changes
during trastuzumab therapy is included in Table 2.

Cardiac side effects, including symptomatic heart failure,
developed in four patients who were previously treated with
chemotherapy containing anthracyclines at a dose exceed-
ing 300 mg/m² and in six patients who were treated with
anthracyclines at doses lower than 300 mg/m² (p = 0.084).
Negative receptor status (either ER or PR) was detected in ten
patients (8%) with symptoms of cardiac side effects. Evi-
dence of cardiac side effects was noted in 25% of patients
with negative ER or PR tumors in comparison with 72 (60%) patients with positive receptor status and without card-
iotoxicity symptoms (p = 0.045). Univariate analysis showed a correlation between cardiac side effects and neg-
ative steroid receptor status (ER/PR) compared to positive
receptor status (6% vs. 3%) (p = 0.00005). In the multivari-
ate analysis ER/PR negative, HER 2 overexpressing breast
cancer patients were significantly more prone to develop
asymptomatic or symptomatic cardiac events during treat-
ment with trastuzumab if presenting with baseline LVEF
between 50% and 60% (p = 0.0001). No relationship was
identified in the study group between cardiotoxicity risk in
trastuzumab treatment and the presence of such risk fac-
tors as age (p = 0.465), menopausal status (p = 0.728), obe-
sity (p = 0.977), hypertension (p = 0.685), diabetes (p = 0.537)
and use of stimulants (p = 0.891).

Sixty-two percent of women in the study group were giv-
en trastuzumab in adjuvant treatment and 38% for metaста-
tic disease of breast cancer. In the group of patients receiv-
ing adjuvant therapy, cardiotoxicity occurred in 6.6% of
patients and in patients treated for metastatic disease in 8.7% of
cases, p = 0.710. Among patients receiving adjuvant treat-
ment a decrease in LVEF was noted in three patients in the
initial stage of therapy (4–8 infusions) and in two patients
at the end of therapy. As for treatment implemented in
metastatic disease, a decrease in LVEF was mainly observed
after 20 infusions. In the group treated for metastatic dis-
ease there was an insignificantly higher incidence of con-
tractility abnormalities compared with the group receiving
adjuvant treatment (8.7% vs. 1.4%, p = 0.141). Also, there was
not significantly higher incidence of fluid accumulation in the
pericardial cavity (2.2% vs. 1.4%, p = 0.739). There were no
differences between the groups in terms of LVEF reduction

Table 2. Symptomatic and asymptomatic cardiac events

| Cardiotoxicity     | NYHA criteria | No. of risk factors | LVEF before trastuzumab (%) | Lowest LVEF value (%) | Trastuzumab continuation | LVEF after completion of therapy (%) |
|--------------------|---------------|---------------------|-----------------------------|-----------------------|--------------------------|-------------------------------------|
| asymptomatic       | II            | 2                   | 52                          | 45                    | yes                      | 55                                  |
| symptomatic        | III           | 3                   | 59                          | 39                    | no                       | 41                                  |
| asymptomatic       | II            | 1                   | 55                          | 43                    | yes                      | 53                                  |
| symptomatic        | IV            | 1                   | 58                          | 35                    | no                       | 38                                  |
| asymptomatic       | II            | 2                   | 60                          | 40                    | no                       | 45                                  |
| asymptomatic       | II            | 3                   | 50                          | 35                    | no                       | 40                                  |
| asymptomatic       | I             | 2                   | 56                          | 46                    | yes                      | 51                                  |
| asymptomatic       | I             | 0                   | 58                          | 45                    | no                       | 48                                  |
| asymptomatic       | I             | 1                   | 70                          | 55                    | yes                      | 60                                  |

= 0.05). A full description of LVEF changes dur-

**Table 2. Symptomatic and asymptomatic cardiac events**

| Cardiotoxicity | NYHA criteria | No. of risk factors | LVEF before trastuzumab (%) | Lowest LVEF value (%) | Trastuzumab continuation | LVEF after completion of therapy (%) |
|----------------|---------------|---------------------|-----------------------------|-----------------------|--------------------------|-------------------------------------|
| asymptomatic   | II            | 2                   | 52                          | 45                    | yes                      | 55                                  |
| symptomatic    | III           | 3                   | 59                          | 39                    | no                       | 41                                  |
| asymptomatic   | II            | 1                   | 55                          | 43                    | yes                      | 53                                  |
| symptomatic    | IV            | 1                   | 58                          | 35                    | no                       | 38                                  |
| asymptomatic   | II            | 2                   | 60                          | 40                    | no                       | 45                                  |
| asymptomatic   | II            | 3                   | 50                          | 35                    | no                       | 40                                  |
| asymptomatic   | I             | 2                   | 56                          | 46                    | yes                      | 51                                  |
| asymptomatic   | I             | 0                   | 58                          | 45                    | no                       | 48                                  |
| asymptomatic   | I             | 1                   | 70                          | 55                    | yes                      | 60                                  |
In the PACS04 study, which was a randomized phase III trial, adding trastuzumab to chemotherapy significantly extended disease-free survival (DFS) and overall survival (OS) without a significant effect on toxicity with the exception of cardiotoxicity in trastuzumab-treated patients [11–16]. The HERA trial demonstrated that trastuzumab in adjuvant treatment (HERA, NSABP B31, FinHER, and BCIRG 006) showed that the addition of trastuzumab to adjuvant therapy significantly extended disease-free survival (DFS) and overall survival (OS) without a significant effect on toxicity with the exception of cardiotoxicity in trastuzumab-treated patients [11–16]. The HERA trial demonstrated that trastuzumab in adjuvant treatment significantly increased 4-year OS rates (89% vs. 87%) and 4-year DFS rates (78% vs. 72%) in comparison with trastuzumab-free therapy [11]. The NSABP B31 and N9831 trials demonstrated that addition of trastuzumab to chemotherapy regimen (paclitaxel and doxorubicin) reduces disease recurrence by 52% and risk of death by 33% compared with chemotherapy alone [16, 17]. In the PACS04 study, which was a randomized phase III trial of women with node-positive early breast cancer, the results contrast with the above-mentioned trials. The results of this study showed that patients who received trastuzumab had a non-significant, 14% reduction in the risk of relapse [18].

Some of the patients experiencing cardiac side effects exhibit typical symptoms of heart failure including reduced exercise tolerance, dyspnea on exertion, tachycardia or signs of fluid retention. But the most common cardiotoxicity seen with trastuzumab is asymptomatic decline in LVEF. In most patients cardiac dysfunction was reversible on discontinuation of trastuzumab therapy and introduction of cardiac therapy [2, 13]. In the HERA trial asymptomatic decline in LVEF was observed in 7.1% of patients and symptoms of heart failure were seen in 1.7% of trastuzumab treated patients [11]. Similarly, in the NSABP B31 and N9831 trials 14.2% of patients discontinued trastuzumab therapy because of asymptomatic decline in LVEF and only 4.7% of patients discontinued therapy due to heart failure [16, 17]. In a study by Serrano et al., performed in elderly patients (age > 70) who were given trastuzumab both in adjuvant therapy and for treatment of metastatic disease, cardiac side effects triggered by trastuzumab developed in 26.7% of patients, including symptoms of heart failure in 8.9% [19]. In the study group, asymptomatic decrease in LVEF was noted in 37% of patients. Cardiotoxicity occurred in 8% of women, including 2% of patients with heart failure symptoms. Cardiac side effects developed in nine patients with baseline LVEF between 50% and 60%, and in just one patient whose baseline LVEF was 70% (p < 0.001). The increase of LVEF was frequently observed in patients with higher BMI (p = 0.05).

Table 3. A comparison of adjuvant therapy with treatment of metastatic disease

| Parameter                        | Trastuzumab in adjuvant treatment (n = 74) | Trastuzumab in metastatic disease (n = 46) | p    |
|----------------------------------|-------------------------------------------|-------------------------------------------|------|
| age > 60 years                   | 13                                        | 8                                         | 0.941|
| hormonal receptor status (ER/PR–) | 26                                        | 22                                        | 0.167|
| radiotherapy                     | 57                                        | 34                                        | 0.698|
| hormone therapy                  | 48                                        | 23                                        | 0.088|
| anthracycline exposure           | 66                                        | 43                                        | 0.428|
| cardiotoxicity                   | 5                                         | 4                                         | 0.710|
| decrease in LVEF                 | 6                                         | 4                                         | 0.852|
| cardiac arrhythmias              | 1                                         | 4                                         | 0.141|
| changes of pericarditis          | 1                                         | 1                                         | 0.739|
| adverse events                   | 2                                         | 1                                         | 0.656|

Discussion

Trastuzumab is the standard care for patients with HER2 (+) breast cancer both for adjuvant therapy and treatment of metastatic disease. Trastuzumab can be combined with chemotherapy regimens containing anthracyclines and taxanes or used in monotherapy. Four major studies of trastuzumab in adjuvant treatment (HERA, NSABP B31, FinHER, and BCIRG 006) showed that the addition of trastuzumab to adjuvant therapy significantly extended disease-free survival (DFS) and overall survival (OS) without a significant effect on toxicity with the exception of cardiotoxicity in trastuzumab-treated patients [11–16]. The HERA trial demonstrated that trastuzumab in adjuvant treatment significantly increased 4-year OS rates (89% vs. 87%) and 4-year DFS rates (78% vs. 72%) in comparison with trastuzumab-free therapy [11]. The NSABP B31 and N9831 trials demonstrated that addition of trastuzumab to chemotherapy regimen (paclitaxel following AC) reduces disease recurrence by 52% and risk of death by 33% compared with chemotherapy alone [16, 17]. In the PACS04 study, which was a randomized phase III trial of women with node-positive early breast cancer, the results contrast with the above-mentioned trials. The results of this study showed that patients who received trastuzumab had a non-significant, 14% reduction in the risk of relapse [18].

Some of the patients experiencing cardiac side effects exhibit typical symptoms of heart failure including reduced exercise tolerance, dyspnea on exertion, tachycardia or signs of fluid retention. But the most common cardiotoxicity seen with trastuzumab is asymptomatic decline in LVEF. In most patients cardiac dysfunction was reversible on discontinuation of trastuzumab therapy and introduction of cardiac therapy [2, 13]. In the HERA trial asymptomatic decline in LVEF was observed in 7.1% of patients and symptoms of heart failure were seen in 1.7% of trastuzumab treated patients [11]. Similarly, in the NSABP B31 and N9831 trials 14.2% of patients discontinued trastuzumab therapy because of asymptomatic decline in LVEF and only 4.7% of patients discontinued therapy due to heart failure [16, 17]. In a study by Serrano et al., performed in elderly patients (age > 70) who were given trastuzumab both in adjuvant therapy and for treatment of metastatic disease, cardiac side effects triggered by trastuzumab developed in 26.7% of patients, including symptoms of heart failure in 8.9% [19]. In the study group, asymptomatic decrease in LVEF was noted in 37% of patients. Cardiotoxicity occurred in 8% of women, including 2% of patients with heart failure symptoms. Cardiac side effects developed in nine patients with baseline LVEF between 50% and 60%, and in just one patient whose baseline LVEF was 70% (p < 0.001). The increase of LVEF was frequently observed in patients with higher BMI (p = 0.05).

Patient age and prior anthracycline therapy are recognized independent risk factors for trastuzumab-induced cardiotoxicity [4, 20]. Age > 60 years was found to be a risk factor in the NSABP B31 trial [16]. An association between increasing age and cardiac toxicity was also observed in the NCTG N9831 trial, in which 15% of patients were aged ≥ 60. In contrast, in the BCIRG 006 trial an influence of older age on cardiac side effects was not reported [13]. In this studied group, older age and history of cardiac diseases had no significant impact on the development of cardiotoxicity. Only patients receiving radiotherapy were more likely to develop cardiotoxicity if they were older (p = 0.0003). Trastuzumab combination with anthracycline-containing chemotherapy regimens increased the incidence of cardiac side effects even to 27% [3]. The risk of cardiac dysfunction increases after a cumulative dose of doxorubicin exceeding 300 mg/m² [20]. The addition of trastuzumab to anthracycline-containing chemotherapy was associated with a higher incidence of heart failure (NYHA III–IV) compared with the combination of trastuzumab with anthracycline-free chemotherapy (BCIRG trial) [13]. In this study 90% of patients received anthracycline-containing therapy, including 23% who received anthracycline doses exceeding 300 mg/m². The HERCULES multicenter, phase I to II trial was conducted to evaluate the cardiac safety of epirubicin/cyclophosphamide plus trastuzumab reg-
in the analyzed group of patients, risk factors for cardiac toxicity included: previous radiotherapy to the left side of the chest (p = 0.05), high BMI, low baseline LVEF (p < 0.001) and negative steroid receptor status (p = 0.045). The impact of anthracycline-containing chemotherapy was not significant (p = 0.08). Patients receiving radiotherapy were more prone to develop cardiotoxicity if they were older (p = 0.0003). Factors such as diabetes, hypertension, menopausal status, use of stimulants or age of the patients did not affect the development of cardiotoxicity. Moreover, cancer advancement was not found to have any prognostic value for cardiac side effects. There was no significant difference between patients receiving adjuvant therapy and patients treated for metastatic disease.

The authors declare no conflict of interest.

References
1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
2. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31.
3. Seidman A, Huds C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.
4. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-600.
5. Freedman NJ, Ginsburg GS. Novel and “neu” therapeutic possibilities for heart failure. J Am Coll Cardiol 2006; 48: 1448-50.
6. de Korte MA, de Vries EG, Lub-de Hooge MN, et al. 111Indium trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43: 2046-51.
7. Sengupta PP, Northfelt DW, Gentile F, Zamarano IL, Khandheria BK. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 2008; 83: 197-203.
8. Fox KF. The evaluation of left ventricular fraction for patients being considered for, or receiving Trastuzumab (Herceptin) therapy [letter]. Br J Cancer 2006; 95: 1454.
9. Stoodley PW, Richards DA, Meikle SR, Clarke J, Hui R, Thomas L. The potential role of echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapy. Heart Lung Circ 2011; 20: 3-9.
10. Duchnowska R, Szmidt S, Szyczyk C, Opolski G. Trudności w monitorowaniu echokardiograficznym leczenia trastuzumabem chorych na raka piersi – opis przypadek i przegląd zaleceń. Kardiol Pol 2008; 66: 895-8.
11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer patients: BCIRG 006 study [abstract]. Breast Cancer Res Treat 2006; 100 (Suppl 1): 52.
12. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ATT) in HER2-positive early breast cancer patients: BCIRG 006 study [abstract]. Breast Cancer Res Treat 2006; 100 (Suppl 1): 52.
13. Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 355: 809-20.
14. Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 2010; 21: 2153-60.
Cardiac side effects of trastuzumab in breast cancer patients – single center experiences

16. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node positive, human epidermal growth factor receptor 2 overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-9.

17. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol 2008; 26: 1231-8.

18. Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 27: 6129-34.

19. Serrano C, Cortés J, De Mattos-Arruda L, et al. Trastuzumab – related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012; 23: 897-902.

20. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab – associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.

21. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322-9.

22. Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 2010; 28: 1473-80.

23. Deroo BJ, Korach KS. Estrogen receptors and human diseases. J Clin Invest 2006; 116: 561-8.

24. Untch M, Rezaii M, Loibl S, et al. Neoadjuvant treatment of HER2 over-expression primary breast cancer with Trastuzumab given concomitantly to epirubicin/cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicancer Intergroup – study “GeparQuattro”: Eur J Cancer 2008; 6: 47.

Address for correspondence

Dr Joanna Huszno
Clinical and Experimental Oncology Department
Maria Skłodowska-Curie Memorial Cancer Center
and Institute of Oncology
Gliwice Branch
Wybrzeże Armii Krajowej 15
44-101 Gliwice, Poland
e-mail: joahus@wp.pl

Submitted: 23.07.2012
Accepted: 22.10.2012